PAX immunoreactivity identifies alveolar rhabdomyosarcoma

American Journal of Surgical Pathology

Volumn 33, Issue 5, 2009, Pages 775-780

  Sullivan, Lisa M ^a   Atkins, Kristen A ^a   Legallo, Robin D ^a,b  

^a UNIVERSITY OF VIRGINIA   (United States)

^b UNIVERSITY OF VIRGINIA MEDICAL CENTER   (United States)

Author keywords

Immunohistochemistry; PAX5; Pediatric blue cell tumor; Rhabdomyosarcoma

Indexed keywords

TRANSCRIPTION FACTOR PAX3; TRANSCRIPTION FACTOR PAX5; TRANSCRIPTION FACTOR PAX7; PAX5 PROTEIN, HUMAN;

ADOLESCENT; ADULT; ARTICLE; CHILD; CHROMOSOME TRANSLOCATION; CONTROLLED STUDY; CROSS REACTION; CYTOGENETICS; EMBRYONAL RHABDOMYOSARCOMA; EWING SARCOMA; FUSION GENE; GENE TRANSLOCATION; GRANULOCYTIC SARCOMA; HEPATOBLASTOMA; HUMAN; HUMAN TISSUE; IMMUNOREACTIVITY; INFANT; LYMPHOBLASTOMA; MAJOR CLINICAL STUDY; NEPHROBLASTOMA; NEUROBLASTOMA; NEWBORN; PRESCHOOL CHILD; PROTEIN EXPRESSION; RHABDOMYOSARCOMA; SCHOOL CHILD; SENSITIVITY AND SPECIFICITY; SMALL CELL SARCOMA; TISSUE MICROARRAY; ACUTE LYMPHOBLASTIC LEUKEMIA; BONE TUMOR; CHEMISTRY; GENE EXPRESSION REGULATION; GENETICS; IMMUNOHISTOCHEMISTRY; KIDNEY TUMOR; LIVER TUMOR; METABOLISM; PATHOLOGY; PREDICTION AND FORECASTING; RETROSPECTIVE STUDY;

ADOLESCENT; B-CELL-SPECIFIC ACTIVATOR PROTEIN; BONE NEOPLASMS; CHILD; CHILD, PRESCHOOL; GENE EXPRESSION REGULATION, NEOPLASTIC; HEPATOBLASTOMA; HUMANS; IMMUNOHISTOCHEMISTRY; INFANT; INFANT, NEWBORN; KIDNEY NEOPLASMS; LIVER NEOPLASMS; NEUROBLASTOMA; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; RHABDOMYOSARCOMA, ALVEOLAR; RHABDOMYOSARCOMA, EMBRYONAL; SARCOMA, EWING'S; SARCOMA, MYELOID; TISSUE ARRAY ANALYSIS; TRANSLOCATION, GENETIC; WILMS TUMOR;

EID: 65449142062     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0b013e318191614f     Document Type: Article

References (19)

1. Adshead JM, Ogden CW, Penny MA, et al. The expression of PAX5 in human transitional cell carcinoma of the bladder: relationship with de-differentiation. BJU Int. 1999;83:1039-1044.
2. Barr FG, Qualman SJ, Macris MH, et al. Genetic heterogeneity in the alveolar rhabdomyosarcoma subset without typical gene fusions. Cancer Res. 2002;62:4704-4710.
3. Baumann Kubetzko FB, Di Paolo C, Maag C, et al. The PAX5 oncogene is expressed in N-type neuroblastoma cells and increases tumorigenicity of a S-type cell line. Carcinogenesis. 2004;25:1839-1846.
4. Chi N, Epstein JA. Getting your Pax straight: Pax proteins in development and disease. Trends Genet. 2002;18:41-47.
5. Davicioni E, Finckenstein FG, Shahbazian V, et al. Identification of a PAX-FKHR gene expression signature that defines molecular classes and determines the prognosis of alveolar rhabdomyosarcomas. Cancer Res. 2006;66:6936-6946.
6. Ford HL. Homeobox genes: a link between development, cell cycle, and cancer? Cell Biol Int. 1998;22:397-400.
7. Hicks J, Mierau GW. The spectrum of pediatric tumors in infancy, childhood, and adolescence: a comprehensive review with emphasis on special techniques in diagnosis. Ultrastruct Pathol. 2005;29: 175-202.
8. Hostein I, Andraud-Fregeville M, Guillou L, et al. Rhabdo-myosarcoma: value of myogenin expression analysis and molecular testing in diagnosing the alveolar subtype: an analysis of 109 paraffin-embedded specimens. Cancer. 2004;101:2817-2824.
9. Kovac CR, Emelyanov A, Singh M, et al. BSAP (Pax5)-importin alpha 1 (Rch1) interaction identifies a nuclear localization sequence. J Biol Chem. 2000;275:16752-16757.
10. Lagergren A, Manetopoulos C, Axelson H, et al. Neuroblastoma and pre-B lymphoma cells share expression of key transcription factors but display tissue restricted target gene expression. BMC Cancer. 2004;4:80.
11. Meza JL, Anderson J, Pappo AS, et al. Analysis of prognostic factors in patients with nonmetastatic rhabdomyosarcoma treated on intergroup rhabdomyosarcoma studies III and IV: the Children's Oncology Group. J Clin Oncol. 2006;24:3844-3851.
12. Mhawech-Fauceglia P, Saxena R, Zhang S, et al. Pax-5 immunoexpression in various types of benign and malignant tumors: a high-throughput tissue microarray analysis. J Clin Pathol. 2006;60: 709-714.
13. Morotti RA, Nicol KK, Parham DM, et al. An immunohistochemical algorithm to facilitate diagnosis and subtyping of rhabdomyosarcoma: the Children's Oncology Group experience. Am J Surg Pathol. 2006;30:962-968.
14. Nishio J, Althof PA, Bailey JM, et al. Use of a novel FISH assay on paraffin-embedded tissues as an adjunct to diagnosis of alveolar rhabdomyosarcoma. Lab Invest. 2006;86:547-556.
15. Parham DM, Qualman SJ, Teot L, et al. Correlation between histology and PAX/FKHR fusion status in alveolar rhabdomyosarcoma: a report from the Children's Oncology Group. Am J Surg Pathol. 2007;31:895-901.
16. Sebire NJ, Malone M. Myogenin and MyoD1 expression in paediatric rhabdomyosarcomas. J Clin Pathol. 2003;56:412-416.
17. Sorensen PH, Lynch JC, Qualman SJ, et al. PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: a report from the children's oncology group. J Clin Oncol. 2002;20:2672-2679.
18. Torlakovic E, Slipicevic A, Robinson C, et al. Pax-5 expression in nonhematopoietic tissues. Am J Clin Pathol. 2006;126: 798-804.
19. Wachtel M, Runge T, Leuschner I, et al. Subtype and prognostic classification of rhabdomyosarcoma by immunohistochemistry. J Clin Oncol. 2006;24:816-822.